# EDGAR Filing Document

**Accession Number:** 0001783036
**File Stem:** 0001213900-25-110759
**Filing Date:** 2025-11
**Character Count:** 10308
**Document Hash:** 86c0658cbfbd0870c305d7850c957bab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-110759.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001213900-25-110759

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewcelX Ltd.
- **CENTRAL INDEX KEY:** 0001783036
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92065
- **FILM NUMBER:** 251485142

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **BUSINESS PHONE:** 41-41-618-80-00

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NLS Pharmaceutics Ltd.
- **DATE OF NAME CHANGE:** 20190719
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Revel Michel
- **CENTRAL INDEX KEY:** 0002095518

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 52C HANASI HARISHON
- **CITY:** REHOVOT
- **PROVINCE COUNTRY:** L3
- **ZIP:** 7630242

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**NewcelX Ltd.**

*(Name of Issuer)*

**Common Shares**

*(Title of Class of Securities)*

**H5835A109**

*(CUSIP Number)*

**Michel Revel**<br>52 HaNasi HaRishon Street<br>Rehovot L3 7630242<br>972-73-7971600

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/30/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **H5835A109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Michel Revel** | Name of reporting person<br>**Michel Revel** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**902985.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**37802.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**902985.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**37802.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**940787.00** | Aggregate amount beneficially owned by each reporting person<br>**940787.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**20.2%** | Percent of class represented by amount in Row (11)<br>**20.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) Consists of (i) 902,985 common shares, par value CHF 0.05 of NewcelX Ltd. (the "Common Shares"), held by Prof. Michel Revel (ii) 18,901 Common Shares held by Revel Family Ltd., and (iii) 18,901 Common Shares issuable upon exercise of common warrants held by Revel Family Ltd. exercisable within 60 days of October 30, 2025, subject to a beneficial ownership limitation of 9.99%. Revel Family Ltd. is controlled by Michel Revel, an equity owner, who holds shared voting and dispositive power over the securities held by Revel Family Ltd and may be deemed to be the controlling shareholder over the securities held by Revel Family Ltd.

(2) Based on 4,558,378 Common Shares issued and outstanding as of October 31, 2025, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on October 29, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares

**(b) Name of Issuer:**
NewcelX Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
The Circle 6, Zurich, V8, 8058

**Item 4. Purpose of Transaction**

The information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person holds all securities of the Issuer for investment purposes only. The Common Shares beneficially owned by the Reporting Person were acquired as follows:

2024 Securities Purchase Agreement

On October 9, 2024, NLS Pharmaceutics Ltd. (now known as the Issuer following the Merger (as defined below)), entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the securities purchase agreement, the Issuer agreed to issue and sell to the investors, in a private placement offering, (i) 806,452 Common Shares, and (ii) common share purchase warrants to purchase 806,452 Common Shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.2 million. The Common Warrants have a term of five years and have an exercise price of $4.25 per share. Pursuant to the securities purchase agreement, the Issuer agreed to grant the investors the right to participate, in the aggregate, in up to fifty percent (50%) of future offerings for one year following the closing of the offering. In addition, the Issuer agreed to not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. The transactions contemplated by the securities purchase agreement closed on October 10, 2024. In connection with this securities purchase agreement, the Reporting Person purchased 189,012 Common Shares and common warrants to purchase 189,012 Common Shares, all with his personal funds. Following the Merger, such Common Shares and common warrants were adjusted per a 1-for-10 reverse split.

Merger Transaction

On November 4, 2024, NLS entered into an Agreement and Plan of Merger, as subsequently amended, with Kadimastem Ltd. ("Kadimastem"). The merger (the "Merger") was completed in 2025, pursuant to which NLS Pharmaceutics (Israel) Ltd., a wholly owned subsidiary of NLS, merged with and into Kadimastem, with Kadimastem continuing as the surviving company and a wholly owned subsidiary of NLS. Following the Merger, the combined company was renamed NewcelX, Ltd. ("NewcelX" or the "Issuer"). In connection with the Merger, each outstanding ordinary share of Kadimastem was exchanged for Common Shares in a final exchange ratio of 7.06 NLS common shares for each Kadimastem ordinary share, or 0.706 Common Shares in exchange for each Kadimastem ordinary share, reflecting the 1-for-10 reverse share split effected by NewCelX in connection with the Merger.

As a result of the Merger, the Reporting Person, who served as the Chief Scientific Officer and a director of Kadimastem, became the Chief Scientific Officer and a director of NewcelX. At the effective time of the Merger, 1,279,639 Kadimastem ordinary shares previously beneficially owned by the Reporting Person were converted into NLS common shares pursuant to the exchange ratio.

The Reporting Person serves as a director of NewcelX and, in such capacity, will be involved in reviewing transactions that may result in operational, strategic, financial or governance changes for NewcelX and may have influence over the corporate activities of NewcelX, including, without limitation, activities which may relate to any and all matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See the responses to rows 11 and 13 on the cover pages of this Schedule 13D for the Reporting Person.

Consists of (i) 902,985 common shares, par value CHF 0.05 of NewcelX Ltd. (the "Common Shares"), held by Prof. Michel Revel (ii) 18,901 Common Shares held by Revel Family Ltd., and (iii) 18,901 Common Shares issuable upon exercise of common warrants held by Revel Family Ltd. exercisable within 60 days of October 30, 2025, subject to a beneficial ownership limitation of 9.99%. Revel Family Ltd. is controlled by Michel Revel, an equity owner, who holds shared voting and dispositive power over the securities held by Revel Family Ltd and may be deemed to be the controlling shareholder over the securities held by Revel Family Ltd.

**(b)**
See responses to rows 7, 8, 9 and 10 on the cover pages of this Schedule 13D for the Reporting Person.

**(c)**
Except as set forth in Item 4 of this Schedule 13D, the Reporting Person, to the best of Reporting Person's knowledge, has not engaged in any transaction with respect to the Common Shares during the sixty days prior to the date of filing this Schedule 13D.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information contained in Items 2, 3, 4 and 5 of this Schedule 13D is incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Michel Revel

**Signature:** /s/ Prof. Michel Revel

**Name/Title:** Prof. Michel Revel

**Date:** 11/14/2025